Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

19.10B

Market cap19.10B

Price-Earnings ratio

15.18

Price-Earnings ratio15.18

Dividend yield

—

Dividend yield—

Average volume

1.66M

Average volume1.66M

High today

$96.30

High today$96.30

Low today

$94.61

Low today$94.61

Open price

$96.23

Open price$96.23

Volume

1.25M

Volume1.25M

52 Week high

$112.29

52 Week high$112.29

52 Week low

$53.56

52 Week low$53.56

Stock Snapshot

Incyte(INCY) stock is priced at $95.60, giving the company a market capitalization of 19.1B. It carries a P/E multiple of 15.18.

As of 2026-03-06, Incyte(INCY) stock has fluctuated between $94.61 and $96.30. The current price stands at $95.60, placing the stock +1.0% above today's low and -0.7% off the high.

Incyte(INCY) shares are trading with a volume of 1.25M, against a daily average of 1.66M.

During the past year, Incyte(INCY) stock moved between $53.56 at its lowest and $112.29 at its peak.

INCY News

TipRanks 4h

Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion

Incyte ( (INCY) ) just unveiled an announcement. On February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Incyte for it...

TipRanks 4h

Incyte announces European Commission approval of Zynyz

Incyte (INCY) “announced that the European Commission has approved Zynyz in combination with carboplatin and paclitaxel for the first-line treatment of adult pa...

Simply Wall St 12h

Incyte’s Cash Flow Gains Reshape Earnings Outlook And Capital Return Options

Incyte, ticker NasdaqGS:INCY, is reporting sustained revenue growth alongside an expansion in free cash flow margins. The company is also showing strong earnin...

Analyst ratings

46%

of 28 ratings

Buy

42.9%

Hold

46.4%

Sell

10.7%

More INCY News

Simply Wall St 7d

Incyte Valuation Check After EMA Boost For Olumiant Alopecia Approval Potential

Incyte (INCY) is back in focus after Eli Lilly and Incyte received a positive opinion from the European Medicines Agency for extending Olumiant to adolescents w...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Willdan

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.